Home > Boards > US Listed > Biotechs >

Cel-Sci (CVM)

CVM RSS Feed
Add CVM Price Alert      Hide Sticky   Hide Intro
Moderator: Foxwoods Man, drkazmd65
Search This Board: 
Last Post: 4/19/2019 7:11:37 PM - Followers: 227 - Board type: Free - Posts Today: 15

 Cel-Sci Corporation (CVM)

http://www.cel-sci.com/

https://www.youtube.com/watch?v=auAihG3rtC4

Products In Development

Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CANCER - MULTIKINE

Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.

Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties.  More...

INFECTIOUS DISEASES - L.E.A.P.S.(TM)**

L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform.  More...

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products

Partnering Philosophy & Corporate Partners

CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of: 

  1. The patients who are/will be treated,
    The scientific, clinical, and commercial development of the medicine and
    CEL-SCI's shareholders.

CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.

Multikine® (Leukocyte Interleukin, Injection):

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.

Current Corporate Partners:

  1. Byron Biopharma
     
      a. Agreement Signed March 2009  
      b. Territory - Republic of South Africa  
      c. Revenue Share  

    Teva Pharmaceuticals Industries Ltd.
     
      a. Agreement Signed August 2008  
      b. Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011.  
      c. Revenue Share  
      d. Website - http://www.tevapharm.com/  

     
    Orient Europharma Co. Ltd.
     
      a. Agreement Signed November 2000  
      b. Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008.  
      c. Revenue Share  
      d. Website - http://www.oep.com.tw/  

     
    IDC-GP Pharm LLC 
     
      a. Agreement signed August 2011  
      b. Territory - Argentina and Venezuela  
      c. Revenue Share  
      d. Website - http://www.gp-pharm.com/  

     

Other Partnering Possibilities:

Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology.  The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.

https://www.prnewswire.com/news-releases/biotech-brief-growing-number-of-ongoing-clinical-trials-for-leukemia-aml-brings-new-hope-300827745.html

http://KillCVMShorts.com/faqs

http://KillCVMShorts.com/idmc

http://KillCVMShorts.com

http://stockcharts.com/freecharts/gallery.html?CVM

http://finance.yahoo.com/q?s=cvm&ql=1

http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833

https://seekingalpha.com/article/4249758-cel-scis-phase-iii-trial-head-and-neck-cancer-analys




 

CVM
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CVM News: Current Report Filing (8-k) 04/15/2019 01:37:58 PM
CVM News: Statement of Changes in Beneficial Ownership (4) 04/12/2019 05:04:48 PM
CVM News: Statement of Changes in Beneficial Ownership (4) 04/12/2019 05:01:07 PM
CVM News: Statement of Changes in Beneficial Ownership (4) 04/12/2019 04:57:53 PM
CVM News: Statement of Changes in Beneficial Ownership (4) 04/12/2019 04:52:44 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#19754  Sticky Note Welcome CVM Newbies sushifishman 04/06/19 08:25:19 AM
#20255   Lightrock, staticmirror79 04/19/19 07:11:37 PM
#20254   Oh good heavens no don't use those from there lightrock 04/19/19 05:28:22 PM
#20253   @Static Does this breakdown Stage 3 and 4 cancers sushifishman 04/19/19 04:16:33 PM
#20252   Article Abstract Trustbaby 04/19/19 03:32:39 PM
#20251   Lightrock, staticmirror79 04/19/19 03:00:05 PM
#20250   Hello and Have a wonderful Easter weekend while Charmed7713 04/19/19 01:01:12 PM
#20249   They’d have to set the new standard of The_Q 04/19/19 11:54:50 AM
#20248   @sun Ugh... Where have you been... lightrock 04/19/19 10:31:06 AM
#20247   Yes SOC is the plan.. pijoe 04/19/19 10:24:04 AM
#20246   Wow, I didn't realize that the dosage regimen sunpillar 04/19/19 10:14:31 AM
#20245   Taiwanese Hospital Minutes sushifishman 04/19/19 07:44:47 AM
#20244   Everyone have a great Easter weekend! Hopefully, we RobotDroid 04/19/19 06:57:19 AM
#20243   @george I am encouraged by AVEO. lightrock 04/19/19 12:32:53 AM
#20242   Warning-Echo chamber subject !!! georgebailey 04/19/19 12:07:30 AM
#20241   Based on debate here I’m not sure that georgebailey 04/19/19 12:02:58 AM
#20240   Good question. They spent all that money building Turney 04/18/19 11:41:57 PM
#20239   Looking forward to that !! georgebailey 04/18/19 11:03:58 PM
#20238   Something to add to this question is the The_Q 04/18/19 09:59:17 PM
#20237   Lightrock I have your answer and i will post Cotton_Farmer 04/18/19 09:24:06 PM
#20236   Greetings, fellow CVM longs! sunpillar 04/18/19 08:30:20 PM
#20235   Thanks Fosco1 04/18/19 06:20:04 PM
#20233   @Fosco Just donated. Don’t need MK to work sushifishman 04/18/19 05:35:50 PM
#20232   Hi Fosco, If Cel-Sci makes it to the Trustbaby 04/18/19 05:18:12 PM
#20231   Indeed... But following Droid's thoughts... lightrock 04/18/19 03:59:46 PM
#20228   board is so light today... just like today's volume tarius729 04/18/19 03:35:30 PM
#20227   @Sushi I guess it's tax crunch time...hope the pressure sab63090 04/18/19 03:13:01 PM
#20226   Nothing like Sept 11. Not one iota. That pijoe 04/18/19 03:12:44 PM
#20225   Beautiful symbol of world history and I am sab63090 04/18/19 03:03:57 PM
#20223   Step away from the pink hat, RobotDroit! Go CVM! Trustbaby 04/18/19 01:11:52 PM
#20222   Wow, board went to sleep, must be reading RobotDroid 04/18/19 01:02:39 PM
#20221   Thanks. yeah he bought 400, never showed, yet RobotDroid 04/18/19 09:53:03 AM
#20220   RobotDroid: Sometimes a block desk is given a large sab63090 04/18/19 09:45:27 AM
#20219   A friend bought shares this morning yet no RobotDroid 04/18/19 08:48:06 AM
#20218   Seems obvious to those outside the echo chamber dyp 04/17/19 11:00:12 PM
#20217   Lightrock good question - I will ask Cotton_Farmer 04/17/19 10:00:35 PM
#20216   Markets closed Friday, tomorrow's trading, who knows? Its RobotDroid 04/17/19 09:58:09 PM
#20215   Accumulating Do not expect low cost stock to be Cotton_Farmer 04/17/19 09:47:53 PM
#20214   * * $CVM Video Chart 04-17-2019 * * ClayTrader 04/17/19 04:20:47 PM
#20213   I was thinking the same thing. They day cvm101 04/17/19 04:15:30 PM
#20212   are shorts getting sufficiently worried enough to try tarius729 04/17/19 04:04:21 PM
#20211   very similar to yesterdays trading action. We may cvm101 04/17/19 03:18:16 PM
#20209   Rooster, nobody is impressed that you can predict Trustbaby 04/17/19 03:17:25 PM
#20208   volume is interesting, correcto mundo? sab63090 04/17/19 03:15:14 PM
#20207   Oh lookie here...a double pump, before the dump!!!! Roosterx4 04/17/19 03:14:43 PM
#20206   FYI and FWIW....I added to my existing position today. sab63090 04/17/19 03:08:13 PM
#20205   I put in a new link on my sab63090 04/17/19 03:04:58 PM
#20204   Yesterday was a powerful reversal day and today sab63090 04/17/19 02:55:05 PM
#20203   End of day surge again? Such weird trading RobotDroid 04/17/19 02:44:53 PM
#20202   I did not. Maybe try her Facebook or Trustbaby 04/17/19 11:55:42 AM
#20201   Yea given we were up over 11% yesterday cvm101 04/17/19 11:50:23 AM
PostSubject